Pharmstandard PHST-Financial and Strategic SWOT Analysis Review

Pharmstandard PHST-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH82561FSA
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pharmstandard (PHST)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharmstandard is pharmaceutical company which carries out the development, manufacture and distribution of advanced pharmaceutical products. The company offers production of APIs and substances and finished pharmaceutical products. It also serves third party in development of biotech drugs. Pharmstandard's product portfolio includes drugs for treatments of cardio-vascular diseases, cancer gastroenterological, neurological, diabetes, contagious diseases, growth hormone deficiency, metabolic disorders and other diseases. The company provides generic pharmaceutical in various forms such as tablets, soluble tablets, pills, powder, gelatin capsules, sachets, ampoules, ointments, sprays, syrups, injections, and solutions. The company serves customers in CIS and Former Soviet Union (FSU) countries. Pharmstandard is headquartered in Dolgoprudny, Moscow Oblast, Russian Federation.

Pharmstandard Key Recent Developments

Apr 29, 2016: Pharmstandard reports FY2015 Audited IFRS Results

Apr 06, 2016: Eisai and PharmStandard Sign Cooperation Agreements in Russia

Jul 10, 2015: Johnson & Johnson and Pharmstandart Sign Agreement For LifeScan Production in Russia

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Pharmstandard-Key Facts 6

Pharmstandard-Key Employees 7

Pharmstandard-Key Employee Biographies 8

Pharmstandard-Major Products and Services 9

Pharmstandard-History 11

Pharmstandard-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Affiliate 14

Joint Venture 14

Section 2-Company Analysis 15

Pharmstandard-Business Description 15

Pharmstandard-Corporate Strategy 16

Pharmstandard-SWOT Analysis 17

SWOT Analysis-Overview 17

Pharmstandard-Strengths 17

Strength-Leading Player in the Russian Pharmaceutical Market 17

Strength-Research and Development Capabilities 17

Strength-Operational Performance 17

Pharmstandard-Weaknesses 18

Weakness-Decline in Pharmaceutical Products Revenue 18

Pharmstandard-Opportunities 19

Opportunity-Product Launches 19

Opportunity-Strategic Agreements 19

Opportunity-New Product Launches 19

Pharmstandard-Threats 20

Threat-Uncertain R&D Outcomes 20

Threat-Government Regulations 20

Threat-Competitive Pressures 20

Pharmstandard-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Pharmstandard, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Pharmstandard, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29

Pharmstandard, Recent Deals Summary 30

Section 5-Company's Recent Developments 32

Apr 29, 2016: Pharmstandard reports FY2015 Audited IFRS Results 32

Apr 06, 2016: Eisai and PharmStandard Sign Cooperation Agreements in Russia 37

Jul 10, 2015: Johnson & Johnson and Pharmstandart Sign Agreement For LifeScan Production in Russia 38

Section 6-Appendix 39

Methodology 39

Ratio Definitions 39

About GlobalData 43

Contact Us 43

Disclaimer 43

List of Figures

Pharmstandard, Performance Chart (2011-2015) 25

Pharmstandard, Ratio Charts 27

Pharmstandard, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Pharmstandard, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 29

List of Tables

Pharmstandard, Key Facts 6

Pharmstandard, Key Employees 7

Pharmstandard, Key Employee Biographies 8

Pharmstandard, Major Products and Services 9

Pharmstandard, History 11

Pharmstandard, Subsidiaries 13

Pharmstandard, Affiliate 14

Pharmstandard, Joint Venture 14

Pharmstandard, Key Competitors 21

Pharmstandard, Ratios based on current share price 22

Pharmstandard, Annual Ratios 23

Pharmstandard, Interim Ratios 26

Pharmstandard, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28

Pharmstandard, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29

Pharmstandard, Recent Deals Summary 30

Currency Codes 39

Capital Market Ratios 39

Equity Ratios 40

Profitability Ratios 40

Cost Ratios 41

Liquidity Ratios 41

Leverage Ratios 42

Efficiency Ratios 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Valenta Farmatsevtika

Teva Pharmaceutical Industries Ltd.

Stada Arzneimittel AG

Sotex Pharm Firm

Rosta ZAO

Pharmsynthez

Biosintez

Bayer Healthcare LLC

Pharmstandard, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8060
Site License
USD 250 INR 16120
Corporate User License
USD 375 INR 24180

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com